Clinical Trial Update: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) [Phase 1]

View source ↗

Summary

Phase 1 study of MK-2118 given as intratumoral monotherapy or in combination with pembrolizumab, and of subcutaneous MK-2118 in combination with pembrolizumab, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• MK-2118
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumor, Lymphoma | Phase 1 | Status: TERMINATED | Results posted: 2024-07-24